{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-234814","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.459940+00:00","generated_at":"2026-05-30T17:25:51.131622+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Inhibikase posts new corporate presentation highlighting PAH clinical program","bullets":["New company presentation made available on investor relations website October 9, 2024.","Presentation focuses on clinical development of disease-modifying therapeutics for pulmonary arterial hypertension (PAH).","No specific financial results, trial data, or guidance disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-234814","json":"https://secwatch.observer/filing/0001193125-24-234814.json","markdown":"https://secwatch.observer/filing/0001193125-24-234814.md","text":"https://secwatch.observer/filing/0001193125-24-234814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524234814/0001193125-24-234814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524234814/d882180d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:25:51.131622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}